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ABSTRACT: This study was designed to assess the effectiveness of a preventive oral protocol in children receiving
antineoplastic treatment for acute lymphoblastic leukemia (ALL) before initiating a larger intervention study. During a
seven month period, fourteen children from two to ten years old with a diagnosis of ALL were evaluated. Patients with
ALL who received a 0.12% chlorhexidine mouth rinse (seven children) were compared to a control group of patients
who were not given the same preventive treatment (seven children) as to the occurrence of oral mucosal complications.
Children in both groups received daily oral hygiene care, and were examined daily by the pediatric dentistry team until
discharge. A significant decrease in the incidence of oral mucositis and ulceration was observed in the children who re-
ceived a 0.12% chlorhexidine mouth rinse (p < 0.05 by Fisher’s exact test). The findings obtained in the present trial
are encouraging, and suggest that the systematic application of a preventive protocol reduces the incidence of oral
complications in children with ALL receiving chemotherapy.
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RESUMO: O objetivo do presente estudo foi verificar a eficácia de um protocolo oral preventivo em crianças com leuce-
mia linfoblástica aguda (LLA), submetidas ao tratamento antineoplásico, antes de iniciar um estudo mais abrangente.
Durante um período de sete meses, foram avaliadas, consecutivamente, quatorze crianças com LLA, de dois a dez anos
de idade. As crianças com LLA que fizeram bochechos com a solução de clorexidina 0,12% (sete crianças) foram com-
paradas com aquelas do grupo controle (sete crianças) no que diz respeito ao surgimento de lesões orais. Todas as cri-
anças do estudo receberam diariamente orientação de higiene oral e foram igualmente examinadas pelo odontopedia-
tra. Observou-se uma diminuição significativa na incidência de mucosite e ulceração oral nas crianças que fizeram
bochecho profilático com clorexidina 0,12% (p < 0,05, teste exato de Fisher). Os achados obtidos no presente estudo
são satisfatórios, e sugerem que uma aplicação sistemática de um protocolo preventivo reduza a incidência de compli-
cações orais em crianças com LLA submetidas à quimioterapia.
DESCRITORES: Leucemia; Quimioterapia; Mucosa oral; Clorexidina.
INTRODUCTION
Immunosuppressive chemotherapy and bone
marrow transplantation have been increasingly
used to treat and, in some cases, cure numerous
malignant conditions14. The systemic sequelae as a
result of these immunosuppressive techniques
induce many oral and dental complications. The
direct and indirect stomatotoxic effects are associ-
ated with the development of ulcerative, hem-
orrhagic, or infectious complications12,14. As a con-
sequence, all these problems can potentially cause
increasing mortality and morbidity14.
Intensive chemoradiotherapy damages the mu-
cosal barrier of the mouth and throat and it is of-
ten associated with severe oral inflammation and
infection, including herpes simplex, candidiasis,
mucositis, and gingivitis1,2,7,9,13. In addition, these
oral complications interfere with patients’ comfort,
nutrition and may lead to a systemic infection ori-
ginated in the mouth19.
The increased risk for systemic fungal infection
and the potential fatal consequences of dissemi-
nated candidiasis in patients receiving bone
marrow transplants or cytotoxic antineoplastic
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therapy has originated several studies about pro-
phylaxis of candidiasis, mucositis, ulceration,
hemorrhage or infection3,5,7-17,19.
The oral health status of hospitalized children
suffering from leukemia or other cancers is gene-
rally poor6. They should be considered as high risk
patients for oral complications, a situation which
requires both suitable dentist and medical te-
ams4,20. However, in some cases, patients undergo-
ing cytotoxic chemotherapy and radiation therapy
often experience severe oral complications during
and after treatment despite the supervised oral
hygiene and conventional antimicrobial regimens9.
A variety of chemical substances has been used
for the prevention and treatment of chemother-
apy-induced oral complications, such as
chlorhexidine5,7,9,12-14,16, vitamin E18, itraconazole10,
fluconazole8, oral sucralfate suspension15, and low
energy helium-neon laser3.
The chlorhexidine mouthwash has been widely
used for the aforementioned purpose. The main
reason for the use of this drug is the fact that it re-
presents an antimicrobial compound and an effec-
tive topical prophylactic agent against oral mucos-
itis and candidiasis9. The relevant literature
presents conflicting results with respect to the
prophylactic use of chlorhexidine in patients with
leukemia or those who have a bone marrow trans-
plant5,7,912-14,16.
The aim of this study was to assess the effecti-
veness of a preventive oral protocol using chlorhe-
xidine mouthrinses in preventing chemothe-
rapy-induced oral mucosal complications in
children receiving intensive chemotherapy for acu-
te lymphoblastic leukemia (ALL) before initiating a
wider intervention study.
MATERIALS AND METHODS
Fourteen children, two to ten years of age
(mean = 7 years), receiving intensive chemothe-
rapy for treatment of acute lymphoblastic leuke-
mia were evaluated. These children were admitted
to the Varela Santiago Hospital Service, Natal, Rio
Grande do Norte, Brazil. They received an identical
intensive chemotherapy regimen for a six-week pe-
riod. The intensive therapy consisted of 6-mercap-
topurine (an oral dose of 50 mg/m2/day during six
weeks), methotrexate (an intravenous dose of
2 mg/m2 in continuous infusion for 24 hours on
days 1, 15, 30 and 45), leucovorin (an oral dose of
15 mg/m2 four times per day, on days 2, 3, 16, 17,
31, 32, 46 and 47) and MADIT intrathecal (a com-
bination of methotrexate 12 mg + cytosine arabi-
noside 70 mg + dexametasone 2 mg/m2) on days 1,
15, 30 and 45. The protocol and informed consent
were reviewed and approved by the ethical review
board, Federal University of Rio Grande do Norte,
Brazil. The informed consent was obtained from
the parents or guardians of all children.
No children had any clinical signs of oral or
esophageal candidiasis nor any other oral compli-
cations on the mucosa before initiating the preven-
tive oral protocol and the intensive chemotherapy.
The chemotherapy regimen employed for the in-
tensive period was identical in all patients. Youn-
ger children were included in the control group.
The preventive oral protocol was performed du-
ring the intensive period of the chemotherapy. It
started at least one day before initiating the inten-
sive chemotherapy and ended ten days after the
end of this period, with an average length of eight
weeks. In the experimental group, seven patients
received a daily preventive protocol consisting of
an oral hygiene care, including twice a day (in the
morning and in the evening) teeth brushing, su-
pervised by guardians, parents and/or dentist,
and mouthrinses with a non-alcoholic solution of
0.12% chlorhexidine (Ao Pharmacêutico, Natal,
RN, Brazil). The seven children of the control group
received a daily oral hygiene care, including twice a
day (in the morning and in the evening) supervised
brushing and mouthrinses with a placebo mouth-
wash. Both groups were then similarly evaluated
daily by the same pediatric dentist for oral muco-
sal complications during the intravenous and in-
trathecal drug administration of the intensive the-
rapy.
Statistical analysis
The data were analyzed statistically by means of
Fisher’s exact test. A p value  0.05 was considered
significant.
RESULTS
During the experimental period all the children
maintained good oral hygiene. A significant decre-
ase in the incidence of mucositis and ulceration in
the children who received the preventive oral pro-
tocol using 0.12% chlorhexidine mouthrinses was
observed (p < 0.05; Fisher’s exact test). One chil-
dren (14.3%) of the experimental group and five
(71.4%) of the control group developed oral muco-
sitis and ulceration (Figures 1 and 2). No other oral
mucosa complication was observed. Mucositis de-
veloped between two and four days after the initial
administration of the intravenous dose of metho-
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trexate, and this was more frequent on the labial
and buccal mucosa. The average durations of mu-
cositis and ulceration was ten and sixteen days,
respectively. The severity of the oral lesions and
their duration in the child who received chlorhexi-
dine mouthrinses were lesser compared to the
control group. No toxicity was observed in this
study. Only the child who developed mucositis in
the experimental group reported a burning sensa-
tion in the mouth associated with the chlorhexidi-
ne mouthwash.
DISCUSSION
The results of this study confirm previous stu-
dies regarding the usefulness of a preventive oral
protocol using a chlorhexidine mouthrinse for the
prevention of chemotherapy-induced oral compli-
cations, including oral mucositis and Candida in-
fections, in children with leukemia receiving inten-
sive chemotherapy9,12-14,16.
In the present study, children who were sub-
mitted to a preventive oral protocol including a
chlorhexidine mouthwash exhibited fewer mu-
cositis lesions. Only one (14.3%) of the seven chil-
dren who used chlorhexidine experienced oral mu-
cositis. These findings indicate that oral soft tissue
disease associated with chemotherapy can be dra-
matically reduced if a prophylactic oral protocol is
applied in association with the chemotherapy.
Consistent with the findings of Ferretti et al.9
(1987) the preventive oral protocol using chlorhe-
xidine mouthrinses can reduce both the incidence
and the severity of oral lesions in children suffe-
ring from leukemia receiving chemotherapy. In ad-
dition to its value in protecting severely immuno-
compromised patients from oral mucosa
complications, chlorhexidine also offers a therape-
utic benefit in the resolution of existing therapy-
induced oral soft tissue disease9.
In contrast, other studies5,7 do not support the
use of chlorhexidine mouthrinses for the preventi-
on of mucositis in patients with bone marrow
transplantation or with leukemia receiving che-
motherapy who are able to maintain good oral
hygiene by mechanical means during their illness.
CONCLUSIONS
The results obtained in this limited number of
patients are promising. We support that the pre-
ventive oral protocol applied in the present study
may be used as an oral complications prophylaxis
for children with leukemia who are receiving inten-
sive chemotherapy. Besides, it may be justified to
obtain and maintain the best possible oral health
in seriously ill patients, because an improvement
of the oral conditions may diminish their suffering
and prevent the spread of serious infections from
the oral cavity. These results have been used to im-
prove the ongoing larger intervention study.
ACKNOWLEDGEMENT
Financial support for this study was provided
by the Conselho Nacional de Desenvolvimento Ci-
entífico e Tecnológico (CNPq).
149
Costa EMM de B, Fernandes MZ, Quinderé LB, Souza LB de, Pinto LP. Evaluation of an oral preventive protocol in children with acute
lymphoblastic leukemia. Pesqui Odontol Bras 2003;17(2):147-50.
FIGURE 1 - Mucositis and ulceration in the labial muco-
sa. Five days after initial administration of intravenous
dose of methotrexate.
FIGURE 2 - Ulceration in the labial mucosa. Six days af-
ter initial administration of intravenous dose of metho-
trexate.
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